#USA #San Francisco #Securities Class Action #Hagens Berman #Hims & Hers

Hims & Hers Health: Facing a Securities Class Action Lawsuit

In recent developments, Hims & Hers Health, Inc. (ticker symbol: HIMS) and key executives are embroiled in a significant securities class action lawsuit. This situation arises from allegations presented in a Federal Trade Commission (FTC) complaint that accuses the company of serious misconduct within its business practices. Hagens Berman, a well-known law firm specializing in corporate accountability, is actively investigating claims and urges individuals who have suffered financial losses to come forward swiftly.

Background on Hims & Hers

Hims & Hers Health offers telehealth services aimed primarily at younger consumers seeking accessible medical advice and prescription services online. The company, publicly traded on the NYSE, has garnered attention for its innovative business model and aggressive marketing strategies. However, recent events have raised questions about the integrity of these operations.

On October 23, 2026, Hagens Berman issued an alert regarding potential securities violations impacting Hims investors. The concerned period for the lawsuit encompasses transactions made between August 4, 2025, and July 29, 2026. Investors are encouraged to submit their information by the deadline of November 2, 2026, to participate in the class action.

Allegations Against Hims & Hers

The crux of the allegations against Hims centers on its business practices related to the handling of consumer health data and the management of subscription billing processes. The FTC's complaint outlines several concerning points:

• - Health Data Privacy Violations: Hims allegedly shared sensitive user information with third-party advertising platforms, despite public assurances of robust privacy protections. This data-sharing reportedly included personal medical conditions and health details sent to giants like Facebook and Snap through tracking mechanisms.
• - Misleading Subscription Practices: The lawsuit also claims Hims violated the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription services without adequate informed consent. Many customers have expressed concerns about being charged for prescriptions almost immediately after submitting intake forms, which goes against the company's stated practice of allowing consultations with medical providers before billing.

These allegations have resulted in significant fallout for Hims & Hers Health. Following the FTC's complaint, Hims' shares plummeted by 14.7%, erasing approximately $970 million from its market capitalization within a single trading day.

Investor Responses and Next Steps

In light of these developments, Hagens Berman is encouraging investors who experienced significant financial setbacks due to these practices to act now. The firm is looking to gather information that could bolster the case against Hims, including any internal documents or non-public insights regarding the company's operational policies.

The lead attorney, Reed Kathrein, emphasizes the importance of understanding whether Hims intentionally misled investors regarding its operational processes and financial status. He continues to invite any whistleblowers with insider knowledge to share their insights, which could be protected under the SEC's whistleblower program, potentially yielding substantial rewards for actionable information.

For investors considering their options, Hagens Berman can be reached directly at 844-916-0895 or through their website dedicated to the Hims investor investigation. The ongoing inquiry highlights the crucial role of transparency and accountability in the corporate landscape, particularly in the healthcare sector where consumer trust is paramount.

Conclusion

As the legal battle unfolds, Hims & Hers Health stands at a critical juncture. Investors are urged to stay informed and take necessary actions, whether through participation in the class action or by seeking consultation with legal experts. The outcome of this lawsuit may not only impact Hims but also set precedents for operational ethics and the handling of consumer data in digital health services. For more detailed information about the investigation and to submit claims, visit Hagens Berman’s dedicated webpage for Hims.

Stay tuned for updates as the situation develops.